Casey Lippmeier
CTO Checkerspot Inc.
Seminars
Thursday 11th June 2026
The Reality of Scaling Novel Lipids for Infant Nutrition: Lessons From 25 Years in Microbial Manufacturing
11:30 am
- Casey Lippmeier, CTO at Checkerspot, draws on 25+ years in microalgae, precision fermentation, and nutritional lipid commercialization to examine how ingredients such as algal DHA moved from scientific promise to widespread use in infant formula
- The session offers a candid look at the realities of scaling novel lipids: strain selection, fermentation, regulatory strategy, cost, supply resilience, and the operational discipline required to serve highly regulated nutrition markets
- Checkerspot’s work on High sn-2 Palmitate Algal Oil and next-generation lipid innovation, is showing how precision fermentation can design the nutritional fats and oils that shape infant formula performance, tolerance, and supply resilience
Thursday 11th June 2026
Closing Panel: Decision Criteria for New Ingredients Shaping the Future of Formula
2:00 pm
- Gain a clear, end-to-end view of how novel ingredients are evaluated, from first screening through pilot trials to full commercial adoption, and what determines decisions
- Define the evidence that moves the market, understanding the evidence package required to advance ingredients, including regulatory readiness, clinical validation, functional performance, and supply security
- Align on realistic timelines and economics, from initial engagement to revenue generation, helping innovators and partners plan investment and scale appropriately
- Set shared priorities for accelerating innovation, synthesize summit insights into actionable industry priorities
